摘要

Authors' objectives: The aim of this rapid Health Technology Assessment was to inform a decision on expanding the influenza vaccination programme in Ireland to include reimbursement of standard quadrivalent influenza vaccines (QIVs) for those aged 50 to 64 years old in the general population (that is, those not at increased risk of sever disease from influenza).